This is the authors' abstract. We don't add key points for this paper.
2016 World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) has shown how molecular features can impact the classification of brain tumors. The continued combination of molecular features with histopathology has led to distinguish tumors with similar histopathologic features but distinct clinical prognosis. The 2021 revised 5. edition of the WHO classification further includes molecular features for CNS tumor categorization including MYB/MYBL1 altered diffuse astrocytoma which is a newly recognized type of low-grade pediatric-type brain tumor. We discuss imaging features of two pediatric-type low-grade gliomas with MYB/MYBL1-mutation that encountered at our institution.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kalelioğlu et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: